Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03368963
Recruitment Status : Recruiting
First Posted : December 11, 2017
Last Update Posted : November 22, 2018
Sponsor:
Collaborators:
Taiho Oncology, Inc.
Ipsen
Information provided by (Responsible Party):
Olatunji Alese, Emory University

Brief Summary:
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have spread to other places in the body or cannot be removed by surgery. Drugs used in the chemotherapy, such as trifluridine/tipiracil hydrochloride combination agent TAS-102 and nanoliposomal irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Condition or disease Intervention/treatment Phase
Colorectal Adenocarcinoma Gastric Adenocarcinoma Metastatic Pancreatic Adenocarcinoma Non-Resectable Cholangiocarcinoma Stage IV Colorectal Cancer Stage IV Gastric Cancer Stage IV Pancreatic Cancer Stage IVA Colorectal Cancer Stage IVB Colorectal Cancer Unresectable Pancreatic Carcinoma Drug: Nanoliposomal Irinotecan Drug: Trifluridine and Tipiracil Hydrochloride Phase 1 Phase 2

Detailed Description:

PRIMARY OBJECTIVES:

I. Determine the recommended phase II dose for the combination of TAS-102 and nanoliposomal irinotecan (nanoliposomal [nal]-IRI). (Phase I)

II. Evaluate the activity of the combination of TAS102 and nal-IRI in previously treated patients with metastatic colorectal cancer and pancreatic cancer. (Phase II)

SECONDARY OBJECTIVES:

I. Define the toxicity profile of the combination of TAS-102 and nal-IRI.

II. Evaluate the response duration, progression free, and overall survival of the combination of TAS-102 and nal-IRI in previously treated patients with metastatic colorectal cancer and pancreatic cancer.

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive nanoliposomal irinotecan intravenously (IV) over 90 minutes on day 1 and trifluridine/tipiracil hydrochloride combination agent TAS-102 orally (PO) twice daily (BID) on days 1-5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days and then every 8 or 12 weeks thereafter.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 64 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Actual Study Start Date : January 30, 2018
Estimated Primary Completion Date : February 29, 2020
Estimated Study Completion Date : February 29, 2020


Arm Intervention/treatment
Experimental: Treatment (Nal-IRI, TAS-102)
Patients receive nanoliposomal irinotecan IV over 90 minutes on day 1 and combination of trifluridine and tipiracil hydrochloride combination agent TAS-102 PO BID on days 1-5. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
Drug: Nanoliposomal Irinotecan
Given IV
Other Names:
  • Irinotecan Liposome
  • Onivyde
  • PEP02
  • Camptosar
  • Liposomal Irinotecan

Drug: Trifluridine and Tipiracil Hydrochloride
Given PO
Other Names:
  • Lonsurf
  • TAS-102
  • Trifluridine/Tipiracil




Primary Outcome Measures :
  1. Incidence of adverse events of trifluridine/tipiracil hydrochloride combination agent TAS-102 in combination with nanoliposomal irinotecan [ Time Frame: Up to 3 years after end of treatment ]
    Assessed using Common Terminology Criteria for Adverse Events version 4.0.

  2. Overall response rate based on modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [ Time Frame: Up to 3 years after end of treatment ]
    Defined as the proportion of patients who achieved a complete response (complete response: disappearance of all target tumors) or a partial response (partial response: ≥ 30% decrease in the sum of the longest diameters of target tumors).


Secondary Outcome Measures :
  1. Progression free survival [ Time Frame: Up to 3 years after end of treatment ]
    Will be evaluated.

  2. Response duration [ Time Frame: From initial response until documented tumor progression, assessed up to 3 years ]
    Will be estimated by Kaplan-Meier method. P values will be two-sided with significance level of .05.

  3. Response rate [ Time Frame: Up to 3 years after end of treatment ]
    Response assessment will be done according to RECIST 1.1 criteria. A repeat imaging scan of the same modality and technique will be repeated after 4 weeks for confirmation of response.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects must have histologic or cytological confirmation of a malignancy that is advanced (metastatic and/or unresectable) with measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1
  • In the dose escalation phase, the trial will be open for patients with stage IV or locally advanced unresectable gastrointestinal adenocarcinomas (gastric, cholangiocarcinoma, pancreatic, colorectal) who have failed at least one prior therapy; subjects must have received, and then progressed or been intolerant to, at least 1 standard treatment regimen in the advanced or metastatic setting
  • In the dose expansion phase, Arm A will be open for 25 patients with pancreatic adenocarcinoma; patients must have histologic diagnosis and either locally advanced unresectable or metastatic disease and have not received prior irinotecan; patients must have received at least one prior line of standard treatment for locally advanced or metastatic disease
  • In dose expansion phase, Arm B will be open for 25 patients with colorectal adenocarcinoma; patients must have histologic diagnosis and metastatic disease and have not received prior irinotecan; patients must have received at least one prior line of standard treatment for locally advanced or metastatic disease
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
  • Adequate organ function
  • Recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy

Exclusion Criteria:

  • History of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible; subjects with other malignancies are eligible if they have been continuously disease free for at least 5 years
  • Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion
  • New York Heart Association (NYHA) class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure
  • Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin
  • Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study
  • Known active central nervous system (CNS) metastases and/or carcinomatous meningitis; subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment; this exception does not include carcinomatous meningitis which is excluded regardless of clinical stability
  • Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies)
  • Inability to take oral medications
  • Homozygous for the UGT1A1*28 allele (UGT1A1 7/7 genotype) only for the phase I part; heterozygotes for UGT1A1*28 (UGT1A11 7/6 genotype) will be allowed to enroll on the trial
  • Patients who are not appropriate candidates for participation in this clinical study for any other reason as deemed by the investigator
  • Patients with history of positive dihydropyrimidine dehydrogenase (DPD) deficiency

Other protocol defined inclusion/exclusion criteria could apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03368963


Contacts
Layout table for location contacts
Contact: Olatunji B. Alese, MD 404-778-2670 olatunji.alese@emory.edu

Locations
Layout table for location information
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Contact: Shabnam Montazeri    404-686-0242    shabnam.montazeri@emory.edu   
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Sheena Abraham    404-778-2670    sheena.abraham@emory.edu   
Emory Saint Joseph's Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Alicia Escobar    678-843-7029    alicia.m.escobar@emory.edu   
Sponsors and Collaborators
Emory University
Taiho Oncology, Inc.
Ipsen
Investigators
Layout table for investigator information
Principal Investigator: Olatunji B. Alese, MD Emory University

Layout table for additonal information
Responsible Party: Olatunji Alese, Principal Investigator, Emory University
ClinicalTrials.gov Identifier: NCT03368963     History of Changes
Other Study ID Numbers: IRB00098958
NCI-2017-01661 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Winship4146-17 ( Other Identifier: Emory University Hospital/Winship Cancer Institute )
First Posted: December 11, 2017    Key Record Dates
Last Update Posted: November 22, 2018
Last Verified: November 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Adenocarcinoma
Pancreatic Neoplasms
Cholangiocarcinoma
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Trifluridine
Irinotecan
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antimetabolites
Antiviral Agents
Anti-Infective Agents